Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB StudyValentina Guarneri, PierFranco Conte, Antonio Frassoldati et al.|Journal of Clinical Oncology|2012Cited by 368
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, <i>ERBB2</i>-Negative Metastatic Breast CancerElisabetta Munzone, L. J. Blacher, Meredith M. Regan et al.|JAMA Oncology|2023Cited by 37
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).Valentina Guarneri, PierFranco Conte, Antonio Frassoldati et al.|Journal of Clinical Oncology|2011Cited by 32
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trialValentina Guarneri, PierFranco Conte, Carlo Alberto Giorgi et al.|European Journal of Cancer|2021Cited by 13
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experienceE.S. Lutrino, Saverio Cinieri, Laura Orlando et al.|Tumori Journal|2019Cited by 6